RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou’s MabSpace Biosciences completed a $40 million B round to support its antibody programs. Based on its proprietary discovery platform, MabSpace has formed discovery partnerships with other biopharmas while it has developed its own innovative portfolio of drug candidates. One month ago, the company began a US Phase I trial of its lead molecule, a PD-L1 antibody for cancer. It expects to begin a similar China trial soon. The B Round was led by Sequoia Capital China and joined by Lilly Asia Ventures and King Star.
Source: China Biotoday
